

## Relationship Between Neutrophil To Lymphocyte Ratio(NLR) And Fragmented QRS in acuteSTEMI Patients Treated With Thrombolysis.

Dr.Balaji Thenrajan<sup>1</sup>, Dr.Selayan Kalaichelvi<sup>2</sup>.

(Senior assistant professor, Department of Medicine, Govt. Royapettah Hospital, Kilpauk Medical College, Chennai-14, India)<sup>1</sup>.

(Associate professor, Department of Medicine, Govt. Royapettah Hospital, Kilpauk Medical College, Chennai-14, India)<sup>2</sup>.

Corresponding Author: Dr. Selayan Kalaichelvi.

---

**Abstract:** Acute coronary syndrome (ACS) is a major cause of morbidity and mortality worldwide where inflammation plays a very important role in the pathogenesis. Studies have shown that neutrophilia and lymphocytopenia along with Neutrophil to lymphocyte ratio(NLR) a recent and novel prognostic marker in ACS<sup>1</sup>. It is economical and easily obtainable from the routine complete blood count. Fragmented QRS in a 12 lead electrocardiogram was proven to be a novel marker<sup>2</sup>. Fragmented QRS complexes are novel ECG signals which are associated with varied conduction abnormalities and the delay of peri- infarct conduction due to myocardial scarring or necrosis<sup>2</sup> and develops mostly within 48 hours during acute myocardial infarction<sup>3</sup>. Some studies also point out that presence of a fragmented QRS might be more specific marker of a previous ischemic event when compared to the age-old, time tested and well known 'Q' wave<sup>6</sup>. NLR can be a cheap alternative though the specificity might be on the lower side<sup>8,9,10,11</sup>. There was one study published demonstrating the relationship between fragmented QRS and Neutrophil to Lymphocyte ratio previously. Hence, this study demonstrated the relationship between the two in patients treated with percutaneous coronary intervention (PCI)<sup>12</sup>. Here in our resource limited situation, we might not have access to a primary PCI and an urgent thrombolysis might be the only solution. There has been no study documented which describes the fragmented QRS in thrombolysed patients. Thus, we aim to investigate the relationship between NLR and fQRS in ST segment elevation myocardial infarction (STEMI) patients undergoing thrombolysis.

**Keywords:** Acute coronary syndrome- fragmented QRS- neutrophil to lymphocyte ratio- thrombolysis- STEMI.

---

Date of Submission: 12-08-2019

Date of Acceptance: 26-08-2019

---

### I. Introduction

Acute coronary syndrome (ACS) is a major cause of morbidity and mortality worldwide. Inflammation plays a very important role in the pathogenesis of ACS as evidenced by the raised inflammatory parameters seen associated with the disease. White blood cell (WBC) count predicts the risk of ACS, is a well proven fact<sup>1</sup>. However there are certain subtypes and other related parameters of the WBC count that has shown stronger association with the prognosis. Studies have shown that neutrophilia is significantly associated with poor outcomes in an ACS. Other studies have shown that lymphopenia is also an accompaniment in ACS<sup>1</sup>. Therefore combining these two parameters and finding the Neutrophil to lymphocyte ratio was thought about. That makes the neutrophil to lymphocyte ratio (NLR) a recent and novel prognostic marker<sup>1</sup>. It is economical and easily obtainable from the routine complete blood count. Among all WBC subtypes, NLR is shown the strongest predictor of inflammatory state and predicts poor outcomes in patients with ACS, and hence found to be a better marker when compared to neutrophilia and lymphopenia.

A 12 lead electrocardiogram still remains a very important investigation in the diagnosis of Acute Coronary Syndrome. Various prognostic markers have been described in the ECG in patients with ACS. Fragmented QRS is such a novel marker<sup>2</sup>. In simple terms additional notches within the QRS complex without a typical bundle branch block can be taken as fragmented QRS. Fragmented QRS complexes are novel ECG signals which are associated with varied conduction abnormalities and the delay of peri- infarct conduction due to myocardial scarring or necrosis<sup>2</sup>. It originates from heterogeneous ventricular activation due to myocardial ischemia or scarring and develops mostly within 48 hours during acute myocardial infarction<sup>3</sup>. Another concept is fragmented QRS arises from myocardial scars<sup>4</sup>. Previous studies demonstrated that systemic inflammation may be associated with the development of fQRS. Ever since fragmented QRS was linked to poor prognosis of ACS in the landmark study by Das *et al*, a lot of studies have emerged, linking fQRS to various entities including

arrhythmias and aneurysms<sup>5,6,7</sup>. However its role in predicting previous ischemic event is well established now. Some studies also point out that presence of a fragmented QRS might be more specific marker of a previous ischemic event when compared to the age-old, time tested and well known  $_{Q'}$  wave<sup>6</sup>. Various studies also described the association of fragmented QRS with complications of ACS including in-hospital mortality and reduced ejection fraction<sup>7</sup>. There are many structured scales for prognosticating acute coronary syndromes. Nonetheless, either neutrophil to lymphocyte ratio or fragmented QRS have emerged in any of them. Further studies are required to identify the importance of these two very simple and inexpensive tools and probably incorporate them into routine practice for risk stratification and triage of patients.

There have been studies conducted linking other markers of inflammation viz. hsCRP to fragmented QRS. However CRP is relatively expensive and might not be a feasible option in resource limited conditions. NLR can be a cheap alternative though the specificity might be on the lower side<sup>8,9,10,11</sup>. There was one study published demonstrating the relationship between fragmented QRS and Neutrophil to Lymphocyte ratio previously. However there have been no Indian studies for the same. This study demonstrated the relationship between the two in patients treated with percutaneous coronary intervention (PCI)<sup>12</sup>. Here in our resource limited situation, we might not have access to a primary PCI and an urgent thrombolysis might be the only solution. There has been no study documented which describes the fragmented QRS in thrombolysed patients. Thus, we aim to investigate the relationship between NLR and fQRS in ST segment elevation myocardial infarction (STEMI) patients undergoing thrombolysis.

## **II. Materials and methods**

- a. Study design:- Cross-sectional observational study
- b. Study period:- 6 months
- c. Study area:- Tertiary health care centre.

### **STUDY POPULATION**

d. Consecutive patients admitted in Government Royapettah Hospital with new acute onset STEMI in a time period of 6 months would be included in the study. The diagnosis of STEMI would be based on ECG and Echo findings.

### **SAMPLE SIZE**

Sample size was calculated using the EpiInfo Application issued by the Center for Disease Control, America. The expected frequency of fragmented QRS in patients with high neutrophil to lymphocyte ratio averages to 70%. Assuming 70% as expected frequency with 6% MOE and 95% Confidence level, the total sample size is 225.

Assuming a non-response rate of 10%, the final sample size is decided as 250.

### **INCLUSION CRITERIA**

Any patient admitted with new acute ST elevation myocardial infarction undergoing thrombolysis. ST elevation MI will be defined as an ST elevation 1 mm in any two or more adjacent precordial or limb leads with Echocardiogram showing aregional wall motion abnormality in the corresponding wall.

### **EXCLUSION CRITERIA**

1. Patients already diagnosed with Coronary Artery Disease
2. Patients with complete or incomplete Bundle Branch Blocks
3. Medical conditions that could affect the WBC counts (acute or chronic infection or inflammatory diseases, hematologic disorder, malignancies, end-stage liver or renal disease, and use of steroid therapy or chemotherapy)
4. Contraindication for thrombolysis
5. Patients with pathological Q waves presenting with or without symptoms
6. Acute MI presenting as new onset LBBB

## **III. Methodology**

Patients admitted in the ICCU with a diagnosis of new onset STEMI based on ECG, meeting the inclusion criteria were included in the study. Patients were asked to fill a semi-structured pre-tested questionnaire to collect information regarding patient demographics, risk factors and co-morbidities. This was used for subset analysis.

Physical examination was performed to rule out comorbid illness. Old medical records were reviewed. Twelve lead ECGs of all patients were taken on admission, after thrombolysis, and at the 24th and 48th hours

after admission. ECG was standardized to 10 mm/mV height amplitude, 25 mm/s speed, and 0.16–100 Hz filter range.

Electrocardiographic analyses were performed by a cardiologist. Percentage of ST segment resolution (STR) was measured by the following formula: (Sum of ST elevations on pre-lysis ECG) – (Sum of ST elevations on post-lysis ECG) / (Sum of ST elevations on pre-lysis ECG) × 100, so total ST segment elevation before and after thrombolysis was calculated. Pathological Q wave, in our study was defined as any Q wave in leads V2–V3 ≥ 0.02 seconds or QS complex in these leads, and a Q wave ≥ 0.03 seconds and N0.1 mV or QS complex in leads I, II, aVL, aVF, or V4–V6 in any two leads of a contiguous lead grouping (I, aVL; V1–V6; II, III, aVF). fQRS was defined as an additional R wave, notching of the R wave, notching of the downstroke or upstroke of the S wave, or more than one R' without a typical bundle branch block. Patients having fQRS at 48th hours ECGs were defined as fQRS (+) group, and patients not having fQRS at 48th hours irrespective of the on admission ECG were defined as fQRS (–) group. The last available ECG was used for the presence of fQRS in case of in-hospital mortality. The number of leads with ST-segment elevation (STE) and ST-segment depression (STD) and number of leads with fQRS were recorded. CBCs of all patients were taken immediately after admission and before starting any medical therapy. Total counts for WBC (and for its subtypes) were evaluated using an automated blood cell counter. NLR was calculated for each patient as the ratio of the neutrophil-to-lymphocyte counts. Other biochemical parameters, including serum creatinine, lipid profile were measured with standard laboratory methods.


Echocardiography was performed on all patients. Thrombolysis was initiated if not otherwise contraindicated. Anticoagulant and antiplatelet therapies were given to all patients according to guidelines.

#### IV. Results

The collected data were analysed with IBM.SPSS statistics software 23.0 Version. To describe about the data descriptive statistics frequency analysis, percentage analysis were used for categorical variables and the mean & S.D were used for continuous variables. To find the significant difference between the bivariate samples in Independent groups the Unpaired sample t-test was used. To find the significance in categorical data Chi-Square test was used similarly if the expected cell frequency is less than 5 in 2×2 tables then the Fisher's Exact was used. In all the above statistical tools the probability value .05 is considered as significant level. A total of 253 subjects were included in the study of which 105 were females and 148 were males. The mean age of presentation was 66.19 ± 11.15. 31.2% of the patients were in the age group of 60-69 years. 7.1% of the population was in the age group of 40-49 years. A statistically significant association was found with age and presence of fQRS (P<0.001). Out of the 31 subjects who were 80 years or older, 28 had evidence of fQRS. There was no statistically significant relation between any sex and fQRS.

**Table 5:** Age distribution

		Frequency	Percent
Valid	40 - 49 yrs	18	7.1
	50 - 59 yrs	66	26.1
	60 - 69 yrs	79	31.2
	70 - 79 yrs	59	23.3
	> = 80 yrs	31	12.3
	Total	253	100.0



**Fig 9:** Age range distribution percentage

**Table 6:** Mean, SD of age in the study population


	N	Minimum	Maximum	Mean	Std. Deviation
AGE	253	40	91	66.19	11.151
Valid N (listwise)	253				

**Table 7:** Age and fQRS

		FQRS		Total	
		FQRS -	FQRS +		
AGE	40 - 49 yrs	Count	9	9	18
		% within	7.8%	6.5%	7.1%
		FQRS			
	50 - 59 yrs	Count	31	35	66
		% within	27.0%	25.4%	26.1%
		FQRS			
	60 - 69 yrs	Count	41	38	79
		% within	35.7%	27.5%	31.2%
		FQRS			
	70 - 79 yrs	Count	31	28	59
		% within	27.0%	20.3%	23.3%
		FQRS			
> = 80 yrs	Count	3	28	31	
	% within	2.6%	20.3%	12.3%	
	FQRS				

**Table 8:** Age and fQRS, Chi-Square tests

Chi-Square Tests			
	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	18.734 <sup>a</sup>	4	.001
Likelihood Ratio	21.678	4	.000
Linear-by-Linear Association	5.354	1	.021
N of Valid Cases	253		



**Fig 10:** Sex Distribution

**Table 9:Sex\* fQRS Crosstab**


		FQRS		Total	
		FQRS -	FQRS +		
Sex	Male	Count	43	61	104
		% within FQRS	37.4%	44.2%	41.1%
	Female	Count	72	77	149
		% within FQRS	62.6%	55.8%	58.9%
Total		Count	115	138	253
		% within FQRS	100.0%	100.0%	100.0%

**Table 10: Sex Distribution**

	FQRS -	FQRS +
Female	37.4%	44.2%
Male	62.6%	55.8%

**Table 11:Chi-Square Tests, Gender\*fQRS**

	Value	df	Asymp.Sig.(2-sided)	ExactSig.(2-sided)	ExactSig.(1-sided)
Pearson Chi-Square	1.202 <sup>a</sup>	1	.273		
Continuity Correction <sup>b</sup>	.937	1	.333		
Likelihood Ratio	1.205	1	.272		
Fisher's Exact Test				.306	.167
Linear-by-Linear Association	1.197	1	.274		
N of Valid Cases	253				



**Fig 11: Sex distribution in both groups**

Out of the 253 subjects, 116 were diabetic of whom 69 had evidence of fQRS. No statistically significant association was found. Similarly a total of 133 subjects were hypertensives, of which 51.4% had presence of fQRS and statistically significant association could be shown. Of the 7 seven patients who had a previous history of cerebrovascular accident, 5 had presence of fQRS. 7 patients had history of chronic kidney disease of which 3.6% had presence of fQRS.

**Table 12: T2DM and fQRS Crosstable**

		FQRS		Total	
		FQRS -	FQRS +		
T2DM	Absent	Count	68	69	137
		% within FQRS	59.1%	50.0%	54.2%
	Present	Count	47	69	116
		% within FQRS	40.9%	50.0%	45.8%
Total		Count	115	138	253
		% within FQRS	100.0%	100.0%	100.0%


**Table 13:** Distribution of diabetics among the two groups

	FQRS -	FQRS +
Absent	59.1%	50.0%
Present	40.9%	50.0%

**Table 14:** T2DM and fQRS; Chi-Square tests

	Value	Df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	2.106 <sup>a</sup>	1	.147		
Continuity Correction <sup>b</sup>	1.755	1	.185		
Likelihood Ratio	2.111	1	.146		
Fisher's Exact Test				.164	.093
Linear-by-Linear Association	2.098	1	.148		
N of Valid Cases	253				

**Fig 12:** Distribution of diabetics in both the groups



**Table 15:** Systemic hypertension and fQRS

		FQRS		Total	
		FQRS -	FQRS +		
SHT	Absent	Count	53	67	120
		% within FQRS	46.1%	48.6%	47.4%
	Present	Count	62	71	133
		% within FQRS	53.9%	51.4%	52.6%
Total		Count	115	138	253
		% within FQRS	100.0%	100.0%	100.0%

**Table 16:** Systemic hypertension: distribution in both groups

	FQRS -	FQRS +
Absent	46.1%	48.6%
Present	53.9%	51.4%

**Table 17:** systemic hypertension and fQRS

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.153 <sup>a</sup>	1	.696		
Continuity Correction <sup>b</sup>	.070	1	.792		
Likelihood Ratio	.153	1	.696		
Fisher's Exact Test				.706	.396
Linear-by-Linear Association	.152	1	.697		
N of Valid Cases	253				




Fig 13: Distribution of Systemic Hypertension in both groups

Table 18:CVA and fQRS

		FQRS		Total	
		FQRS -	FQRS +		
CVA	Absent	Count	113	133	246
		% within FQRS	98.3%	96.4%	97.2%
	Present	Count	2	5	7
		% within FQRS	1.7%	3.6%	2.8%
Total		Count	115	138	253
		% within FQRS	100.0%	100.0%	100.0%

Table 19: Distribution if CVA

	FQRS -	FQRS +
Absent	98.3%	96.4%
Present	1.7%	3.6%

Table 20:Chi-Square tests – CVA and fQRS

	Value	df	Asymp.Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.828 <sup>a</sup>	1	.363		
Continuity Correction <sup>b</sup>	.275	1	.600		
Likelihood Ratio	.862	1	.353		
Fisher's Exact Test				.460	.305
Linear-by-Linear Association	.824	1	.364		
N of Valid Cases	253				




Fig 14: Distribution of CVA

**Table 21: CKD and fQRS**

		FQRS		Total
		FQRS -	FQRS +	
CKD	Absent	Count	113	133
		% within FQRS	98.3%	96.4%
	Present	Count	2	5
		% within FQRS	1.7%	3.6%
Total		Count	115	138
		% within FQRS	100.0%	100.0%


**Table 22: Distribution of CKD**

	FQRS -	FQRS +
Absent	98.3%	96.4%
Present	1.7%	3.6%


**Table 23: Chi-Square tests – CKD and fQRS**

	Value	df	Asymp. Sig.(2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.828 <sup>a</sup>	1	.363		
Continuity Correction <sup>b</sup>	.275	1	.600		
Likelihood Ratio	.862	1	.353		
Fisher's Exact Test				.460	.305
Linear-by-Linear Association	.824	1	.364		
N of Valid Cases	253				

**Fig 15: Distributon of CKD**




The mean length of hospital stay was 5.75± 1.114 days for the fQRS+ group and 5.74±1.109 for the fQRS- group.



**Fig 16: Mean length of hospital stay**




The mean duration of chest pain was  $4.17 \pm 2.38$  days for the fQRS+ group and  $4.38 \pm 2.50$  for the fQRS- group.




**Fig 17:** Mean duration of chest pain

The BMI was  $24.56 \pm 3.40$  days for the fQRS+ group and  $24.77 \pm 3.87$  for the fQRS- group.




**Fig 18:** Mean BMI

The mean leucocyte count was 7932.04 with a SE of  $\pm 115.66$  for the fQRS+ group and 7877.53 with a standard error  $\pm 110.19$  for the fQRS- group.




**Fig 19:** Mean WBC count

The mean neutrophil count was 5978.83 with a standard error of 93.52 for the fQRS+ group and 5430.70 with a standard error±96.75 for the fQRS- group.




**Fig 20:** Mean neutrophil count

The mean lymphocyte count was 5978.83 with a standard error of 93.52 for the fQRS+ group and 5430.70 with a standard error±96.75 for the fQRS- group.



**Fig 21:** Mean lymphocyte count

The mean NLR was  $4.70 \pm 1.14$  for the fQRS+ group and  $3.19 \pm 1.07$  for the fQRS-group.




**Fig 22:** Mean NLR

Our patient cohort was divided into two groups according to the presence of fQRS. When patients with fQRS compared to patients with non-fQRS, baseline clinical characteristics, MI localization, and treatment modalities were similar.

**Table 24:**Mean, SD and SE of mean of variuos parameters in both groups

Group Statistics		N	Mean	Std. Deviation	Std. Error Mean
FQRS					
AGE	FQRS +	138	67.62	12.130	1.033
	FQRS -	115	64.46	9.618	.897
LOS	FQRS +	138	5.75	1.114	.095
	FQRS -	115	5.74	1.109	.103
ch. Pain- DUR	FQRS +	138	4.17	2.358	.201
	FQRS -	115	4.38	2.570	.240
BMI	FQRS +	138	24.56	3.40	0.29
	FQRS -	115	24.77	3.87	0.36
WBC	FQRS +	138	7932.04	1358.70	115.66
	FQRS -	115	7877.53	1181.69	110.19
NEUTROPHILS	FQRS +	138	5978.83	1098.57	93.52
	FQRS -	115	5430.70	1037.56	96.75
LYMPHOCYTES	FQRS +	138	1341.24	382.50	32.56
	FQRS -	115	1834.79	548.57	51.15
NLR	FQRS +	138	4.70	1.14	0.10
	FQRS -	115	3.19	1.07	0.10
EF	FQRS +	138	48.36	13.201	1.124
	FQRS -	115	53.75	13.126	1.224


However, patients with fQRS had lower left ventricular ejection fraction (LVEF). The mean EF was 48.36± 1.124 for the fQRS+ group and 53.75 ± 1.224 for the fQRS- group.



**Fig 23:**Mean ejection fraction in both groups

In addition, WBC, neutrophils, and NLR were significantly higher, whereas lymphocytes were significantly lower in patients with fQRS compared to patients with non-fQRS.

An NLR ≥ 3.75 was found to predict a lower EF with a specificity of 76.50% and a sensitivity of 76.10%. The frequency of fQRS and the number of leads with fQRS were significantly higher for the group with NLR ≥ 3.75. Out of the 253 subjects 120 were below the cut off and 133 were above the cut off. Out of the 120 with a low NLR 33 had presence of fQRS and out of the 133 above the cut off 105 had presence of fQRS.



Diagonal segments are produced by ties.

**Fig 24:** ROC curve for NLR

**Area Under the Curve**

Test Result Variable(s): NLR

**Table 25:** AUC of ROC for NLR

Area	Std. Error <sup>a</sup>	Asymptotic Sig. <sup>b</sup>	Asymptotic 95% Confidence Interval	
			Lower Bound	Upper Bound
.832	.027	.0005	.780	.884

<b>Coordinates of the Curve</b>								
Test Result Variable(s): NLR								
Positive if								
Greater Than or Equal To <sup>a</sup>	Sensitivity	1						
		Specificity						
.24390	1.000	.000	2.44060	.971	.817	2.80717	.949	.539
1.24695	1.000	.991	2.44896	.971	.809	2.81497	.942	.539
1.26570	1.000	.983	2.48672	.971	.800	2.82263	.942	.530
1.50696	1.000	.974	2.52776	.971	.791	2.83090	.942	.522
1.74923	1.000	.957	2.53803	.971	.774	2.83274	.942	.513
1.83980	1.000	.948	2.55022	.971	.765	2.83667	.942	.504
1.93598	1.000	.939	2.56154	.971	.757	2.84857	.935	.504
1.97917	1.000	.930	2.58145	.971	.748	2.85973	.935	.496
2.00222	1.000	.913	2.59940	.971	.739	2.86399	.935	.487
2.04469	1.000	.904	2.60214	.971	.722	2.87727	.935	.478
2.10729	1.000	.896	2.60859	.971	.713	2.89337	.935	.470
2.14683	.993	.896	2.61761	.971	.704	2.90370	.928	.470
2.16534	.993	.887	2.62395	.971	.696	2.91033	.928	.461
2.17110	.993	.878	2.62845	.971	.687	2.91389	.928	.452
2.18152	.993	.870	2.64643	.971	.678	2.92996	.928	.443
2.20222	.986	.870	2.66410	.971	.670	2.94385	.928	.435
2.23232	.986	.861	2.67677	.971	.661	2.95794	.920	.435
2.25429	.978	.861	2.69221	.971	.652	2.97381	.920	.426
2.28428	.971	.861	2.69878	.971	.635	2.98810	.913	.426
2.32840	.971	.852	2.70782	.971	.626	3.00617	.913	.417
2.37456	.971	.843	2.71761	.964	.626	3.01598	.906	.417
2.41622	.971	.835	2.72457	.964	.617	3.03064	.906	.409
2.43411	.971	.826	2.73394	.964	.609	3.06124	.906	.400
			2.73872	.964	.591	3.09130	.899	.400
			2.76242	.964	.583	3.10270	.899	.391
			2.78702	.964	.574	3.10736	.891	.391
			2.78956	.964	.565	3.11244	.891	.383
			2.79123	.957	.565	3.11436	.891	.374
			2.79583	.957	.557	3.12414	.884	.374

*Relationship Between Neutrophil To Lymphocyte Ratio(NLR) And Fragmented QRS Inacute STEMI*

3.16430	.877	.374
3.19961	.877	.357
3.21590	.870	.357
3.23892	.862	.357
3.27641	.855	.357
3.33818	.848	.357
3.40056	.841	.357
3.43934	.841	.348
3.45196	.833	.348
3.47299	.826	.348
3.50195	.826	.339
3.51649	.819	.339
3.52374	.819	.330
3.52855	.819	.322
3.53767	.819	.313
3.56139	.812	.313
3.59735	.812	.304
3.61771	.804	.304
3.62099	.804	.296
3.63377	.797	.296
3.64888	.797	.287
3.65248	.790	.287
3.65408	.783	.287
3.65556	.775	.287
3.67787	.775	.278
3.70156	.775	.270
3.70350	.775	.261
3.70528	.775	.252
3.71012	.775	.243
3.73178	.768	.243

3.75450	.761	.235
3.76660	.761	.226
3.78710	.754	.226
3.80051	.746	.217
3.80676	.739	.217
3.84792	.739	.209
3.88611	.732	.209
3.89181	.732	.200
3.89664	.732	.191
3.89928	.725	.191
3.90833	.717	.191
3.92119	.710	.191
3.92781	.703	.191
3.93743	.703	.183
3.94844	.696	.183
3.96066	.696	.174
3.98801	.688	.174
4.01338	.681	.174
4.04000	.681	.165
4.08993	.674	.165
4.12542	.674	.157
4.13099	.674	.148
4.13616	.667	.148
4.14924	.659	.148
4.16199	.652	.148
4.17517	.652	.139
4.20989	.645	.139
4.24266	.638	.139
4.25483	.630	.139
4.27051	.630	.130

4.28314	.623	.130
4.29717	.616	.130
4.31727	.609	.130
4.34444	.609	.122
4.36402	.601	.122
4.41111	.594	.122
4.46824	.587	.122
4.48967	.580	.122
4.50318	.580	.113
4.51937	.580	.104
4.53891	.572	.104
4.54724	.565	.104
4.55342	.565	.096
4.57689	.558	.096
4.60567	.551	.096
4.62019	.551	.087
4.64583	.543	.087
4.68066	.536	.078
4.69502	.529	.078
4.70881	.522	.078
4.73611	.514	.078
4.76067	.507	.078
4.78567	.500	.078
4.80179	.493	.078
4.80745	.486	.078
.83850	.478	.070
4.89719	.471	.070
4.92900	.464	.070
4.95797	.457	.070
4.99054	.449	.070

4.99722	.442	.070
5.01249	.435	.070
5.03350	.428	.070
5.12101	.420	.070
5.33307	.413	.070
5.47006	.406	.070
5.48011	.399	.070
5.49064	.391	.070
5.50044	.384	.070
5.50715	.377	.070
5.51942	.370	.070
5.53089	.362	.070
5.54293	.355	.070
5.56111	.341	.070
5.57114	.333	.070
5.58167	.326	.070
5.61691	.319	.070
5.65467	.319	.061
5.66550	.312	.061
5.66909	.304	.061
5.67504	.297	.061
5.67968	.290	.061
5.68986	.275	.061
5.70441	.268	.061
5.71252	.261	.061
5.71530	.254	.061
5.72289	.246	.061
5.73561	.239	.061
5.74122	.232	.061
5.74312	.225	.061

5.74734	.217	.061
5.75529	.217	.052
5.76091	.210	.052
5.77402	.203	.052
5.78761	.196	.052
5.79322	.188	.052
5.80111	.181	.052
5.81460	.181	.043
5.82628	.167	.043
5.83378	.159	.043
.84481	.152	.043
5.85313	.145	.043
5.86451	.145	.035
5.88030	.138	.035
5.89852	.130	.035
5.92151	.123	.035
5.93948	.123	.026
5.94750	.116	.026
5.96074	.109	.026
5.99925	.101	.026
6.02740	.094	.026
6.04375	.087	.026
6.06205	.080	.026
6.06956	.072	.026
6.07917	.065	.026
6.08558	.058	.026
6.11364	.051	.026
6.15187	.043	.026
6.16548	.036	.026
6.16879	.036	.017

6.21171	.036	.009
6.28605	.029	.009
6.42783	.022	.009
6.53976	.022	0.000
6.54348	.014	0.000
6.72175	.007	0.000
7.90000	0.000	0.000

**Table 26:**Co-ordinates of ROC

**Table 27:Independent Samples Test**

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
AGE	Equal variances assumed	8.907	.003	2.264	251	.024	3.162	1.396	.412	5.913
	Equal variances not assumed			2.312	250.411	.022	3.162	1.368	.469	5.856
LOS	Equal variances assumed	.003	.957	.052	251	.959	.007	.140	-.269	.284
	Equal variances not assumed			.052	243.258	.959	.007	.140	-.269	.284
ch. Pain-DUR	Equal variances assumed	1.189	.277	-.673	251	.502	-.209	.310	-.820	.402
	Equal variances not assumed			-.668	234.150	.505	-.209	.313	-.825	.407
BMI	Equal variances assumed	.001	.974	-.468	251	.640	-.21379	.45691	1.11367	.68608
	Equal variances not assumed			-.462	229.156	.644	-.21379	.46226	1.12461	.69703
WBC	Equal variances assumed	1.232	.268	.337	251	.736	54.506	161.785	264.123	373.134
	Equal variances not assumed			.341	250.527	.733	54.506	159.750	260.118	369.129

NEUTROPHILS	Equal variances assumed	.427	.514	4.052	251	.0005	548.138	135.263	281.743	814.532
	Equal variances not assumed			4.074	247.067	.000	548.138	134.560	283.107	813.169
LYMPHOCYTES	Equal variances assumed	5.163	.024	-8.400	251	.000	-493.552	58.754	609.265	377.839
	Equal variances not assumed			-8.139	198.037	.0005	-493.552	60.638	613.132	373.973
NLR	Equal variances assumed	4.002	.047	10.782	251	.000	1.511183	.140163	1.235136	1.787229
	Equal variances not assumed			10.842	247.290	.0005	1.511183	.139388	1.236643	1.785723
EF	Equal variances assumed	1.932	.166	-3.239	251	.0005	-5.386	1.663	-8.660	-2.111
	Equal variances not assumed			-3.241	243.324	.001	-5.386	1.662	-8.659	-2.112

### V. Discussion

Neutrophil to lymphocyte ratio and fragmented QRS are two novel markers in prognosticating STEMI. There have been many studies recently describing the importance of each. A high NLR has been associated with poor ejection fraction and high in hospital mortality. Similarly presence of fragmented QRS has been associated with poor ejection fraction, higher incidence of arrhythmias and increased mortality. There was one previous study which showed that a high NLR was associated with more leads having fQRS. Further combined presence of both high NLR and fQRS was associated with higher in-hospital mortality. Previous studies showed in patients who had resolved Q waves after an MI but with evidence of fragmentation of QRS had worse prognosis including increased risk of cardiac events. *Varriale et al* suggested the etiology of fQRS to be myocardial scar. *Bayes de Luna et al* proposed the etiology to be abnormality of late depolarized basalzones.

Zazula et al addressed the question of admission day NLR being a significant diagnostic tool. In their study it was proved that noncardiac chest pain patients reported lowest admission NLR versus ST-elevation MI patients who reported the highest NLR. Other forms of ACS ranked somewhere in between these two. NLR is cheap and easily repeatable, making it an important prospective tool in evaluation of chest pain. There also have been studies conducted linking CRP which is a marker of acute-phase inflammation with prognostication of MI. It can act as a marker for thrombus formation as well. Studies evaluating CRP and NLR in acute MI showed high levels of both and these were linked to thrombus formation as well. There was a study conducted with levels of CRP and fragmented QRS and it showed a significant relation between high levels of CRP and presence of fragmented QRS in ECG. However CRP and hsCRP are expensive and not easily available. NLR can thus be utilized as a surrogate marker for CRP and hence of thrombus formation as well as predicting high

likelihood of having a fragmented QRS in ECG.

In our study it was found that a high total leucocyte count was significantly associated with presence of fQRS. Similarly it was associated significantly with a high neutrophil count and low lymphocyte count. It showed strong association with high NLR as well. High NLR had an inverse relation with ejection fraction in both fQRS positive patients and fQRS negative patients.

A cut off value for NLR was found out to be 3.75 from our study. An  $NLR \geq 3.75$  was found to predict a lower EF with a specificity of 76.50% and a sensitivity of 76.10%. The frequency of fQRS and the number of leads with fQRS were significantly higher for the group with  $NLR \geq 3.75$ . Out of the 253 subjects 120 were below the cut off and 133 were above the cut off. Out of the 120 with a low NLR 33 had presence of fQRS and out of the 133 above the cut off 105 had presence fQRS. This shows the high preponderance of patients with a high NLR to have fQRS in the ECG. The mean ejection fraction of the group with fQRS was lower than the mean ejection fraction of the group without fQRS. The cut-off value of NLR has been variable in different studies. In studies linking NLR and ACS, the cut-off values have been ranging from 3.2 to 5.7. More studies with larger sample size done from India are required to stipulate the normal range for this.

This study hence clearly underlines the importance of using NLR as a tool to prognosticate MI. However, NLR is a non-specific marker of inflammation; it has been found to be raised in various conditions ranging from chronic liver disease to acute cerebrovascular accident. An elevated NLR is seen in many conditions including hypertension, metabolic syndrome, diabetes mellitus, thyroid disorders, kidney or liver failure, malignancies including solid tumors like RCC and also in hematological malignancies, local or systemic infection

This reduces the specificity of using NLR as a sole indicator for prognostication of STEMI patients. That brings in the role fragmented QRS. It is clearly seen in this study that the mean ejection fraction of the fQRS+ group was lesser than that of fQRS- group.

The cause of fragmented QRS is a much debated topic. At first it was speculated to have arisen from myocardial scars. A later argument was that it was a result of abnormalities due to non-homogenous depolarization of ventricles. But this is not substantiated by ability of the tool - presence of fQRS to predict arrhythmias and SCD. It lacks in this aspect. Another observation in our study was the significant relation between age and fQRS. Out of the 31 subjects who were 80 years or older, 28 had evidence of fQRS. A study by Chia-Ying Liu *et al.* showed increased myocardialfibrosis associated with older age. This might explain that fQRS might actually be due to myocardial scarring.

Fragmented QRS was not found to have any significant association with any sex. It also seemed to be unaffected by diabetes, hypertension, CKD or CVA. The number of subjects in our study with CVA and CKD were too low; hence this might not be accurate. The BMI also did not have an effect of presence of fragmented QRS. It is known that hypertension frequently is present along with diabetes. This greatly amends the risk of cardiovascular events. Therefore it makes sense that well controlled hypertension would reduce cardiovascular events in diabetics when compared to non-diabetics. A patient of diabetes mellitus with hypertension should be on antihypertensive therapy. The antihypertensive agents to be considered are, but not limited to, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics, calcium channel blockers, and beta-blockers. The agent of choice has to be chosen. There is a lot of controversy at present about which is the best agent for the same. However, in our study patients with co-existing hypertension and diabetes also did not show any statistically significant difference between the fQRS+ and the fQRS- group. This might be also because of the fact that the number of patients with hypertension and diabetes were less. Hence the significance of this particular finding is dubious.

Outcome prediction and risk stratification are of utmost significance in CAD management. Even though there are various scoring scales that are available in practice for risk stratification of patients with ACS, none of them really uses either NLR or fQRS. Many studies have dictated the association of these two parameters separately with poor prognosis in ACS. In this study we have shown that combining these two parameters might give a better specificity to this. However further studies are required for the same.

Demographics as seen in our study show that men were affected more than women. There was no statistically significant relation of either sex with presence of fQRS. As described above, age of 80 years or more were found to have high risk of having fQRS.

## **VI. Conclusion**

1. A high NLR is associated with a higher risk of having a fragmented QRS in the ECG.
2. The presence of fragmented QRS would mean a reduced ejection fraction and hence more left ventricular systolic dysfunction.
3. Fragmented QRS is most likely due to myocardial scarring and its incidence increases with age. It shows the importance of inflammation and scarring in the pathogenesis of STEMI.
4. fQRS is hence a cheap tool and doesn't require a special equipment, technique or expertise – it is always lying in the ECG. It can form an easy tool for risk stratification of MI.
5. An elevated on admission  $NLR > 3.75$  is associated with development of left ventricular systolic dysfunction in patients with acute STEMI.



6. A high admission NLR can be utilized for additional risk stratification of the patient so that these patients watched for subsequent development of complications of acute STEMI.
7. NLR is a simple and inexpensive tool which can be a novel biomarker for inflammation.
8. Inflammation might be an important causative factor for development of complications in patients with acute STEMI.
9. Neutrophilia, Lymphopenia and a high NLR is inversely proportional to the ejection fraction following a STEMI, and would mean a poor left ventricular systolic function.
10. Diabetes and hypertension does not independently cause fragmentation of QRS
11. Combined use of NLR and fQRS in a risk stratification tool might help identifying patients prone for severe left ventricular dysfunction.

### **LIMITATIONS OF THE STUDY**

The study involved only patients with STEMI. Patients with Unstable angina and NSTEMI were not included. The role of inflammation and presence of fQRS in this population also have to be studied. Biomarkers of myonecrosis were not used in the analysis as it was not available for all patients as it was not feasible to do it for all cases. Also we have included only the patients who underwent thrombolysis as a treatment for STEMI.

### **References**

- [1]. Budzianowski J, Pieszko K, Burchardt P, Rzeźniczak J, Hiczkiewicz J. The Role of Hematological Indices in Patients with Acute Coronary Syndrome. *Disease Markers*.2017;2017:3041565.
- [2]. Das MK, Suradi H, Maskoun W, et al. Fragmented wide QRS on a 12-lead ECG: A sign of myocardial scar and poor prognosis. *CircArrhythmElectrophysiol* 2008;1:258–268
- [3]. DasMK, Khan B, Jacob S, et al. Significance of a fragmented QRS complex versus a Q wave in patients with coronary artery disease. *Circulation*. 2006;113:2495–2501
- [4]. Das MK, Saha C, El Masry H, et al. Fragmented QRS on a 12-lead ECG: a predictor of mortality and cardiac events in patients with coronary artery disease. *Heart Rhythm*2007;4:1385–1392
- [5]. Mahenthiran J. et al. Fragmented QRS complexes not typical of a bundle branch block: A marker of greater myocardial perfusion tomography abnormalities in coronary artery disease. *Journnuc card*2007;5:347-351
- [6]. Golberger J.J, Greenstein E. Fragmented QRS for risk prediction: Picking up the pieces.*j.hrthm*.2007;08:01510.1016
- [7]. Gungor B *et al.* Prognostic Value of QRS Fragmentation in Patients with Acute Myocardial Infarction: A Meta-Analysis.*Ann Noninvasive Electrocardiol* 2016;00(0):1–9
- [8]. Sezer M., Okcular I., Goren T., et al. Association of haematological indices with the degree of microvascular injury in patients with acute anterior wall myocardial infarction treated with primary percutaneous coronary intervention. *Heart*.2007;93(3):313–318.
- [9]. Kalay N., Dogdu O., Koc F., et al. Hematologic parameters and angiographic progression of coronary atherosclerosis. *Angiology*.2012;63(3):213–217.
- [10]. Wang X., Zhang G., Jiang X., Zhu H., Lu Z., Xu L. Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: a meta-analysis of observational studies. *Atherosclerosis*. 2014;234(1):206–213.
- [11]. Tamhane U. U., Aneja S., Montgomery D., Rogers E.-K., Eagle K. A., Gurm H. S. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. *The American Journal of Cardiology*.2008;102(6):653–657.
- [12]. Tanriverdi Z, Colluoglu T, Dursun H, Kaya D. The Relationship between neutrophil-to-lymphocyte ratio and fragmented QRS in acute STEMI patients treated with primary PCI. *Journal of Electrocardiology*. 2017. 312 –316
- [13]. Fuster V, Harrington RA, Narula J, Eapen Z J. Hurst's the heart. 14<sup>th</sup> edition, 2018
- [14]. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. *J Am CollCardiol*.2005;46:937-954.
- [15]. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*.2013;127:529-555.
- [16]. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am CollCardiol*.2014;64:e139-228.
- [17]. Braunwald E, Morrow DA. Unstable angina: is it time for arequiem? *Circulation*.2013;127:2452-2457.
- [18]. Braunwald E. Unstable angina. A classification. *Circulation*.1989;80:410-414.
- [19]. Campeau L. Letter: grading of angina pectoris. *Circulation*.1976;54:522-523.
- [20]. Goldberg A, Yalonetsky S, Kopeliovich M, Azzam Z, MarkiewiczW. Appropriateness of diagnosis of unstable angina pectoris in patients referred for coronary arteriography. *ExpClinCardiol*.2008;13:133-137.
- [21]. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am CollCardiol*2000;36:959-969.
- [22]. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Eur Heart J*. 2012;33:2551-2567.
- [23]. Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. *Ann Intern Med*. 1993;118: 81-90.
- [24]. Leise MD, Locke GR 3rd, Dierkhising RA, Zinsmeister AR, Reeder GS, Talley NJ. Patients dismissed from the hospital with a diagnosis of noncardiac chest pain: cardiac outcomes and health care utilization. *Mayo Clin Proc*.2010;85:323-330.
- [25]. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med*.2011;364:226-235.
- [26]. Ibanez B, Fuster V, Jimenez-Borreguero J, Badimon JJ. Lethal myocardial reperfusion injury: a necessary evil? *Int J Cardiol*.2011;151:3-11.
- [27]. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. *J Clin Invest*.2013;123:92-100.
- [28]. Jennings RB. Historical perspective on the pathology of myocardial ischemia/reperfusion injury. *Circ Res*.2013;113:428-438.
- [29]. Jennings RB, Ganote CE, Reimer KA. Ischemic tissue injury. *Am J Pathol*.1975;81:179-198.

- [30]. Buja LM. Myocardial ischemia and reperfusion injury. *Cardiovasc Pathol*. 2005;14:170-175.
- [31]. Kloner RA, Ellis SG, Lange R, Braunwald E. Studies of experimental coronary artery reperfusion. Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage. *Circulation*. 1983;68(Suppl.I):I-8-I-15.
- [32]. Roberts CS, Schoen FJ, Kloner RA. Effect of coronary reperfusion on myocardial hemorrhage and infarct healing. *Am J Cardiol*. 1983;52:610-614.
- [33]. Tani M, Neely JR. Role of intracellular Na<sup>+</sup> in Ca<sup>2+</sup> overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. *Circ Res*. 1989;65:1045-1056.
- [34]. Piper HM, Abdallah Y, Schafer C. The first minutes of reperfusion: a window of opportunity for cardioprotection. *Cardiovasc Res*. 2004;61:365-371.
- [35]. Mingels AM, Joosen IA, Versteyleen MO et al. High-sensitivity cardiac troponin T: risk stratification tool in patients with symptoms of chest discomfort. *PLoS ONE* 7(4), e35059(2012).
- [36]. Zazula AD, Précóma-Neto D, Gomes AM et al. An assessment of neutrophils/lymphocytes ratio in patients suspected of acute coronary syndrome. *Arq. Bras. Cardiol*. 90(1), 31–36(2008).
- [37]. Li DB, Hua Q, Liu Z et al. Association between inflammatory mediators and angiographic morphologic features indicating thrombus formation in patients with acute myocardial infarction. *Chin. Med. J*. 122(15), 1738–1742(2009).
- [38]. Muhmmad Suliman MA, Bahnacy Juma AA, Ali Almadhani AA, Pathare AV, Alkindi SS, Uwe Werner F. Predictive value of neutrophil to lymphocyte ratio in outcomes of patients with acute coronary syndrome. *Arch. Med. Res*. 41(8), 618–622(2010).
- [39]. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. *Am. J. Cardiol*. 102(6), 653–657(2008).
- [40]. Bhat, Teli, Rijal et al., Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. *Expert Rev. Cardiovasc. Ther*. 11(1), 55–59(2013).
- [41]. Sunbul, M., Gerin, F., Durmus, E., Kivrak, T., Sari, I., Tigen, K. and Cincin, A., 2014. Neutrophil to lymphocyte and platelet to lymphocyte ratio in patients with dipper versus non-dipper hypertension. *Clinical and Experimental Hypertension*, 36(4), pp.217-221.
- [42]. LATE Study Group, 1993. Late Assessment of Thrombolytic Efficacy (LATE) study withalteplase 6–24 hours after onset of acute myocardial infarction. *Lancet*, 342(8874), pp.759-66.
- [43]. Nunn, A.J., Rusen, I.D., Van Deun, A., Torrea, G., Phillips, P.P., Chiang, C.Y., Squire, S.B., Madan, J. and Meredith, S.K., 2014. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. *Trials*, 15(1), p.353.

Dr. Balaji Thenrajan. “Relationship Between Neutrophil To Lymphocyte Ratio(NLR) And Fragmented QRS Inacute STEMI Patients Treated With Thrombolysis..” *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*, vol. 18, no. 8, 2019, pp 41-58.